Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy.

Tuyaerts S, Amant F.

Vaccines (Basel). 2018 Aug 25;6(3). pii: E56. doi: 10.3390/vaccines6030056. Review.

2.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
3.

Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model.

Verheecke M, Hermans E, Tuyaerts S, Souche E, Van Bree R, Verbist G, Everaert T, Van Houdt J, Van Calsteren K, Amant F.

Reprod Sci. 2018 Jan 1:1933719118756771. doi: 10.1177/1933719118756771. [Epub ahead of print]

PMID:
29439620
4.

In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.

Vanderstraeten A, Tuyaerts S, Everaert T, Van Bree R, Verbist G, Luyten C, Amant F.

Int J Mol Sci. 2016 Sep 9;17(9). pii: E1525. doi: 10.3390/ijms17091525.

5.

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).

Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, Van Gool SW, Vergote I, Amant F.

Methods Mol Biol. 2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18.

PMID:
27236806
6.

Potential Therapeutic Targets in Uterine Sarcomas.

Cuppens T, Tuyaerts S, Amant F.

Sarcoma. 2015;2015:243298. doi: 10.1155/2015/243298. Epub 2015 Oct 21. Review.

7.

In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer.

Vanderstraeten A, Everaert T, Van Bree R, Verbist G, Luyten C, Amant F, Tuyaerts S.

J Immunother. 2015 Jul-Aug;38(6):239-49. doi: 10.1097/CJI.0000000000000085.

PMID:
26049547
8.

The immune system in the normal endometrium and implications for endometrial cancer development.

Vanderstraeten A, Tuyaerts S, Amant F.

J Reprod Immunol. 2015 Jun;109:7-16. doi: 10.1016/j.jri.2014.12.006. Epub 2015 Jan 8. Review.

PMID:
25613542
9.

Dendritic cell immunotherapy in uterine cancer.

Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW.

Hum Vaccin Immunother. 2014;10(7):1822-7. doi: 10.4161/hv.28716.

10.

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations.

Madondo MT, Tuyaerts S, Turnbull BB, Vanderstraeten A, Kohrt H, Narasimhan B, Amant F, Quinn M, Plebanski M.

J Transl Med. 2014 Jun 23;12:179. doi: 10.1186/1479-5876-12-179.

11.

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.

Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F.

Cancer Immunol Immunother. 2014 Jun;63(6):545-57.

12.

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW.

Anticancer Res. 2013 Dec;33(12):5495-500.

PMID:
24324087
13.

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW.

Anticancer Res. 2013 Sep;33(9):3855-9.

PMID:
24023319
14.

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.

Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A.

J Immunol Methods. 2012 Mar 30;377(1-2):23-36. doi: 10.1016/j.jim.2011.12.010. Epub 2012 Jan 16.

PMID:
22269772
15.

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B.

J Immunother. 2011 Jun;34(5):448-56. doi: 10.1097/CJI.0b013e31821dcb31.

PMID:
21577140
16.

Dendritic cell therapy for oncology roundtable conference.

Tuyaerts S.

J Immune Based Ther Vaccines. 2011 Jan 12;9(1):1. doi: 10.1186/1476-8518-9-1.

17.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, Fran├žois V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

18.

Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.

Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, Neyns B, Thielemans K.

Mol Ther. 2008 Jun;16(6):1170-80. doi: 10.1038/mt.2008.77. Epub 2008 Apr 22.

19.

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.

Michiels A, Tuyaerts S, Bonehill A, Heirman C, Corthals J, Thielemans K.

Methods Mol Biol. 2008;423:155-63. doi: 10.1007/978-1-59745-194-9_10.

PMID:
18370196
20.

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A.

Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. Epub 2007 May 15. Review.

PMID:
17503040
21.

Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.

Tuyaerts S, Van Meirvenne S, Bonehill A, Heirman C, Corthals J, Waldmann H, Breckpot K, Thielemans K, Aerts JL.

J Leukoc Biol. 2007 Jul;82(1):93-105. Epub 2007 Apr 20.

PMID:
17449724
22.

CD83 expression on dendritic cells and T cells: correlation with effective immune responses.

Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, Thielemans K, Breckpot K.

Eur J Immunol. 2007 Mar;37(3):686-95.

23.

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.

Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P.

J Immunol. 2006 Nov 15;177(10):6769-79.

24.

Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.

Michiels A, Breckpot K, Corthals J, Tuyaerts S, Bonehill A, Heirman C, Thielemans K, Aerts JL.

Gene Ther. 2006 Jul;13(13):1027-36. Epub 2006 Mar 2.

PMID:
16511519
25.

Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response.

Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts C, Heirman C, Thielemans K.

J Leukoc Biol. 2005 Oct;78(4):898-908. Epub 2005 Jul 21.

PMID:
16037410
26.

Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.

Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, Van Meirvenne S, Dullaers M, Allard S, Brasseur F, van der Bruggen P, Thielemans K.

Gene Ther. 2005 May;12(9):772-82.

PMID:
15750615
27.

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.

Dullaers M, Breckpot K, Van Meirvenne S, Bonehill A, Tuyaerts S, Michiels A, Straetman L, Heirman C, De Greef C, Van Der Bruggen P, Thielemans K.

Mol Ther. 2004 Oct;10(4):768-79.

28.

Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells.

Breckpot K, Corthals J, Heirman C, Bonehill A, Michiels A, Tuyaerts S, De Greef C, Thielemans K.

Hum Gene Ther. 2004 Jun;15(6):562-73.

PMID:
15212715
29.

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K.

J Immunol. 2004 Jun 1;172(11):6649-57.

31.

Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells.

Tuyaerts S, Michiels A, Corthals J, Bonehill A, Heirman C, de Greef C, Noppe SM, Thielemans K.

Cancer Gene Ther. 2003 Sep;10(9):696-706.

PMID:
12944989
32.

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K.

J Immunol Methods. 2002 Jun 1;264(1-2):135-51.

PMID:
12191517

Supplemental Content

Loading ...
Support Center